Dr David John Addis, MD | |
334 Farnsworth Ave, Bordentown, NJ 08505 | |
(609) 298-1823 | |
Not Available |
Full Name | Dr David John Addis |
---|---|
Gender | Male |
Speciality | General Practice |
Location | 334 Farnsworth Ave, Bordentown, New Jersey |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1770656068 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 25MA02546000 (New Jersey) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr David John Addis, MD 334 Farnsworth Ave, Bordentown, NJ 08505 Ph: (609) 298-1823 | Dr David John Addis, MD 334 Farnsworth Ave, Bordentown, NJ 08505 Ph: (609) 298-1823 |
News Archive
Dostoyevsky and Tolstoy portrayed Russians as a brooding, complicated people, and ethnographers have confirmed that Russians tend to focus on dark feelings and memories more than Westerners do. But a new University of Michigan study finds that even though Russians tend to brood, they are less likely than Americans to feel as depressed as a result.
Just like our senses of hearing and vision, our sense of touch plays an important role in how we perceive and interact with the world around us.
Rigel Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug designation to Fostamatinib, Rigel's oral spleen tyrosine kinase (SYK) inhibitor which is currently in Phase 3 clinical studies in patients with chronic immune thrombocytopenic purpura (ITP).
An international team of researchers, led by scientists at the University of California, San Diego and Yale University schools of medicine, have identified a form of autism with epilepsy that may potentially be treatable with a common nutritional supplement.
› Verified 1 days ago